May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral ... preclinical data for KT-621, its potent ...

These interim data demonstrate that Ruxoprubart, administered as monotherapy, was safe, well-tolerated, and met all primary efficacy endpoints. Ruxoprubart achieved transfusion avoidance ...

Kymera Therapeutics has completed its Phase 1 healthy volunteer trials for KT-621, with data to be reported in ... company advancing a new class of oral small molecule degrader medicines for ...

offering best-in-class cooling, improved device reliability, and a lower total cost of ownership. Fabric8Labs and Wiwynn are redefining what's possible in data center cooling — combining ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

INFO:__main__:Importing compiled proto cylc.flow.ws_messages_pb2 INFO:__main__:Writing PNG diagram to /tmp/ws_messages_pb2.png ...

Republicans are overwhelmingly making gains in working-class counties. Republicans are overwhelmingly making gains in working-class counties. Democrats are improving almost exclusively in ...

Learn theories about the nature and determinants of crime, and how to contrast these theories in real life, using data analytic and data science techniques. Use data and data analytic methods to ...

Learn theories about politics and international relations, and how to contrast these theories in real life, using data analytic and data science techniques. Learn how to use data and data analytic ...